Award
National Cancer Institute 1R42CA287679-01
Clinical testing of Listeria-TT and Gemcitabine in a Phase I clinical trial with PDAC patients
Recipient
Not specified
Awarded
May 29, 2024
Identifier
1R42CA287679-01
Award for a Phase I clinical trial testing Listeria-TT and Gemcitabine in PDAC patients, including manufacturing and safety assessments.
Description
This project involves a clinical trial for a novel immunotherapeutic approach targeting pancreatic ductal adenocarcinoma (PDAC) using Listeria-TT and Gemcitabine. The project includes manufacturing, pathology, toxicology, and clinical response assessments, with a focus on bringing the therapy to clinical testing.